We compared the effector functions and cytotoxicity of these CAR T cell variants against a panel of tumor cell lines with varying levels of human MSLN expression: NCI-H226/KO (MSLN-negative), MSTO-211H (MSLN-low), NCI-H226 (MSLN-intermediate), and MSTO-211H/hMSLN (MSLN-high), which is MSTO-211H engineered to overexpress human MSLN (Figure 3, B and C). The gene discussed is MSLN; the disease is neoplasm.